Log in or Sign up for Free to view tailored content for your specialty!
Lupus News
VIDEO: Hydroxychloroquine not associated with increased QTc in RA
In this video, Dana DiRenzo, MD, MHS, instructor of medicine at Johns Hopkins, highlighted two important studies presented at ACR 2020.
Denosumab superior to alendronate in raising spinal BMD in long-term glucocorticoid users
Among patients using long-term glucocorticoids, denosumab is superior to alendronate in increasing bone mineral density in the spine after 1 year, according to a speaker at ACR Convergence 2020.
Log in or Sign up for Free to view tailored content for your specialty!
BIIB059 safe, efficacious in systemic lupus erythematosus
BIIB059 significantly reduces total active joint counts among patients with systemic lupus erythematosus, with a rate of serious adverse events and infection similar to placebo, according to a speaker at ACR Convergence 2020.
Systemic autoimmune rheumatic disease linked to higher end-organ failure risk in COVID-19
Patients with systemic autoimmune rheumatic diseases who contract COVID-19 may have a higher risk for end-organ failure than those without such diseases, according to a speaker at ACR Convergence 2020.
Simpler language, slower speech may improve lupus medication adherence
Optimizing patient-provider communication and enhancing patient self-efficacy may improve medication adherence rates among patients with systemic lupus erythematosus, according to results presented at the ACR Convergence 2020 meeting.
Anifrolumab bested placebo across multiple domains in SLE
Anifrolumab is superior to placebo for improved BILAG-2004 and SLEDAI-2K domain scores, as well as in mucocutaneous and musculoskeletal domains, among patients with systemic lupus erythematosus, according to a speaker at ACR Convergence.
Hydroxychloroquine not associated with prolonged heart rhythm intervals in RA, lupus
Treatment with hydroxychloroquine does not impact corrected QT length among patients with rheumatoid arthritis or systemic lupus erythematosus, even after adjusting for confounders, according to a speaker at ACR Convergence.
NOBILITY: Gazyva sustains safety, efficacy against lupus nephritis over 2 years
Obinutuzumab provides sustained clinical benefit through 2 years among patients with lupus nephritis, with treatment efficacy maintained 18 months after the final infusion, according to data presented at ACR 2020.
Risk for stroke three times higher among Black patients with lupus
Among Black patients with lupus, the risk for stroke is three times higher than white patients, and the risk for ischemic heart disease is 24 times higher, according to a presenter at ACR Convergence 2020 virtual meeting.
Standardized outcome measures may advance lupus drug development
Simple, standardized outcome measures, including steroid-sparing, could advance lupus drug development, while clarifying the lupus spectrum may improve diagnosis time and patient understanding, according to a speaker at ACR Convergence.
-
Headline News
‘Truly alarming’: Life expectancy gap in the US now up to 20 years
November 22, 20243 min read -
Headline News
Autoantibodies present in long COVID, but not a ‘smoking gun’ for new autoimmune disease
November 25, 20242 min read -
Headline News
Cardiovascular disease deaths rising among younger adults living in rural areas
November 15, 20243 min read
-
Headline News
‘Truly alarming’: Life expectancy gap in the US now up to 20 years
November 22, 20243 min read -
Headline News
Autoantibodies present in long COVID, but not a ‘smoking gun’ for new autoimmune disease
November 25, 20242 min read -
Headline News
Cardiovascular disease deaths rising among younger adults living in rural areas
November 15, 20243 min read